Why is Alivus Life falling/rising?

As of 06-Nov, Alivus Life Sciences Ltd is currently priced at 893.85, reflecting a decrease of 11.8 points or 1.3%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total decline of 2.47% during this period. It has also underperformed its sector by 0.53% today. The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past year, Alivus has generated a return of -18.67%, significantly underperforming the market, which has seen a return of 1.73%. Despite a high management efficiency with a return on equity (ROE) of 25.32% and a low debt-to-equity ratio, the company has shown poor long-term growth, with net sales growing at an annual rate of only 4.49% over the last five years.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has declined by 1.77% over the past week, while the Sensex has decreased by only 1.30%. This underperformance is further highlighted by the stock's year-to-date decline of 9.62% compared to the Sensex's gain of 6.62%. The stock's negative returns and flat results, particularly in June 2025, have contributed to a lack of investor confidence, despite rising investor participation indicated by a significant increase in delivery volume. The stock is currently trading at a premium compared to its peers' average historical valuations, which may also deter potential investors.